Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of September 2023. The filing, dated September 5, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
The filing text does not disclose material changes versus prior periods. The content is limited to the procedural incorporation of a press release.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risks, contingencies, or unusual items are not detailed within the body of this Form 6-K. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Key Facts for Investor Verification
- Verify the content of the press release dated September 5, 2023 (Exhibit 99.1), as this filing contains no substantive operational or financial data.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer.